(NASDAQ: ELTX) Elicio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Elicio Therapeutics's earnings in 2026 is -$40,185,000.On average, 4 Wall Street analysts forecast ELTX's earnings for 2026 to be -$36,210,113, with the lowest ELTX earnings forecast at -$37,782,806, and the highest ELTX earnings forecast at -$34,068,655. On average, 3 Wall Street analysts forecast ELTX's earnings for 2027 to be -$34,263,333, with the lowest ELTX earnings forecast at -$32,919,673, and the highest ELTX earnings forecast at -$35,271,078.
In 2028, ELTX is forecast to generate -$40,882,386 in earnings, with the lowest earnings forecast at -$39,279,155 and the highest earnings forecast at -$42,084,809.